Abstract Representing 2%-3% of adult cancers, renal cell carcinoma (RCC) accounts for
90% of renal malignancies and is the most lethal neoplasm of the urologic system. Over the …

Characterization of renal tumors is critical to determine the best therapeutic approach and
improve overall patient survival. Because of increased use of high-resolution cross-sectional …

Purpose The objective was to determine the safety and clinical activity of atezolizumab
(MPDL3280A), a humanized programmed death-ligand 1 (PD-L1) antibody, in renal cell …

Purpose Patient-reported outcomes may help inform treatment choice in
advanced/metastatic renal cell carcinoma (RCC), particularly between approved targeted …

Objectives To discriminate low grade (Fuhrman I/II) and high grade (Fuhrman III/IV) clear cell
renal cell carcinoma (CCRCC) by using CT-based radiomic features. Methods 161 and 99 …

This research innovatively combines FT-IR, Raman spectroscopy and their first-derivative
spectroscopy to develop a rapid diagnosis method for renal cell carcinoma (RCC). After …

Mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase. It is
ubiquitously expressed in cells and is a therapeutic target for the cancer treatment arsenal …

Background: This retrospective register study assessed overall survival (OS) and influential
factors on OS in Swedish renal cell carcinoma (RCC) patients. Methods: Using three merged …

Introduction: Renal cell carcinoma (RCC) is a highly immunogenic neoplasm, and cytokine-
based immunotherapies have been used for decades with limited success. In recent years …

Lack of appropriate models that recapitulate the complexity and heterogeneity of urological
tumours precludes most of the preclinical reagents that target urological tumours from …